Globalspace Technologies IPO Review & Recommendations

Globalspace Technologies IPO Review by Dilip Davda (Apply)

[Dilip Davda]  No harm in giving this greedily priced offer a miss. Update 07/24/2017 After interaction with the merchant bankers, ipo valuation is done in line with global peers which trades at more than 8 times P/E of this company. Peers shown in prospectus are not comparable in true sense as they are not in healthcare segment. GSTL derives over 60% revenue from healthcare biz and is rapidly growing. FY 16 bottom-line decline is due to R and D and product development provisions. Management is confident of maintaining the growth in top and bottom lines. This is the fourth mandate from merchant banker and the last IPO opened at 5% premium to offer price on listing day. Based on this we have revised conclusion as: Conclusion : Investment may be considered for short to long term. (Subscribe) Read detail review...